Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Netflix benefits from shift to DTC media, sports pivot, and content rationalization, driving revenue and free cash growth.

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...

Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...

For investors, Google might be a great play on AI in general, but the biotech aspect will be a tiny segment in a very large company. So, this article will review publicly listed companies that are ...

Of all the biotech companies, those in the research and discovery stage are the riskiest investments, as it’s not yet clear if the company will succeed or fail. Once a company has developed a ...

In addition, we were treated to an official key art poster and character profile posters – here's a look: Michelle Yeoh as Georgiou in Star Trek: Section 31, streaming on Paramount+, 2024.

That said, anything can happen during a clinical trial, so investing in a biotech company that doesn't yet have products on the market involves some risk. But if you can accept that, scooping up ...